Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Linton

Showing results (231-240 of 265) with videos related to

Pageof 27
Sort By:
Medical and Veterinary Entomology|December 4, 2003
Phylogenetic status and matrilineal structure of the biting midge, Culicoides imicola, in Portugal, Rhodes and IsraelJ F Dallas, R H Cruickshank, Y-M Linton, et al.
Pediatric Pulmonology|January 14, 2017
Comparison of sitting and supine forced vital capacity in collagen VI-related dystrophy and laminin α2-related dystrophyKatherine G Meilleur, Melody M Linton, Joseph Fontana, et al.
British Journal of Haematology|March 10, 2016
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphomaToby A Eyre, Kim M Linton, Phillipa Rohman, et al.
The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses|June 9, 2020
Assessing Motor Function in Congenital Muscular Dystrophy Patients Using AccelerometryTokunbor A Lawal, Joshua J Todd, Jeffrey S Elliott, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Advances in Therapy|May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre CohortNicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Pageof 27

Showing results (231-240 of 265) with videos related to

Sort By:
Pageof 27
Medical and Veterinary Entomology|December 4, 2003
Phylogenetic status and matrilineal structure of the biting midge, Culicoides imicola, in Portugal, Rhodes and IsraelJ F Dallas, R H Cruickshank, Y-M Linton, et al.
Pediatric Pulmonology|January 14, 2017
Comparison of sitting and supine forced vital capacity in collagen VI-related dystrophy and laminin α2-related dystrophyKatherine G Meilleur, Melody M Linton, Joseph Fontana, et al.
British Journal of Haematology|March 10, 2016
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphomaToby A Eyre, Kim M Linton, Phillipa Rohman, et al.
The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses|June 9, 2020
Assessing Motor Function in Congenital Muscular Dystrophy Patients Using AccelerometryTokunbor A Lawal, Joshua J Todd, Jeffrey S Elliott, et al.
British Journal of Haematology|September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive settingToby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Advances in Therapy|May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre CohortNicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Hematological Oncology|August 7, 2019
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLToby A Eyre, Catherine Hildyard, Angela Hamblin, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Pageof 27